Skip to content

Study · Randomized controlled trial · n = 18 · 2025

8 results

Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes: Insights from a One-Year Follow-Up Study.

Tóth LI, Harsányi A, Csiha S, Molnár Á, Lőrincz H, Nagy AC, Paragh G, Harangi M, Sztanek F

International journal of molecular sciences20 Jun 2025Cited by 5 (Europe PMC)

PMID40649729 (opens in a new tab)PMCIDPMC12250273 (opens in a new tab)DOI10.3390/ijms26135951 (opens in a new tab)PepBankPUB-40649729
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

Recent studies have demonstrated the efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in enhancing glycemic control, regulating body weight, and modulating lipid metabolism. However, their effects on lipoprotein subfractions have not been clarified. The objective of this 52-week, single-center, randomized trial was to compare the effects of subcutaneous semaglutide administered once weekly and oral sitagliptin administered once daily on anthropometric measurements and lipoprotein subfractions measured by Lipoprint gelelectrophoresis in patients with type 2 diabetes mellitus (T2DM). A total of 34 obese individuals with T2DM were enrolled in the study and randomly assigned to receive semaglutide (n = 18) or sitagliptin (n = 16). Thirty-one age- and body weight-matched non-diabetic obese individuals served as controls. Semaglutide treatment resulted in significant reductions in body mass index (BMI), waist circumference, and HbA1c, along with improvements in lipid parameters, including reductions in LDL cholesterol and non-HDL cholesterol levels, and redistribution of LDL and HDL subfractions toward a less atherogenic profile. Conversely, sitagliptin elicited modest glycemic improvements without substantial alterations in lipid composition. Multivariate regression analysis demonstrated that fluctuations in lipoprotein subfractions were not influenced by changes in BMI or HbA1c. These results support the pleiotropic metabolic benefits of semaglutide and its potential role in managing the cardiometabolic risk of T2DM.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In obese adults with type 2 diabetes, 52 weeks of subcutaneous semaglutide significantly reduced BMI.

    In plain wordsIn obese adults with type 2 diabetes, a year of semaglutide lowered body mass index.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody mass index
    Study

    n = 18

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Semaglutide treatment resulted in significant reductions in body mass index (BMI), waist circumference, and HbA1c
    2 context sentences
    Summary · context
    The objective of this 52-week, single-center, randomized trial was to compare the effects of subcutaneous semaglutide administered once weekly and oral sitagliptin administered once daily on anthropometric measurements and lipoprotein subfractions measured by Lipoprint gelelectrophoresis in patients with type 2 diabetes mellitus (T2DM).
    Summary · context
    A total of 34 obese individuals with T2DM were enrolled in the study and randomly assigned to receive semaglutide (n = 18) or sitagliptin (n = 16).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In obese adults with type 2 diabetes, 52 weeks of subcutaneous semaglutide significantly reduced waist circumference.

    In plain wordsIn obese adults with type 2 diabetes, a year of semaglutide reduced waist size.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist circumference
    Study

    n = 18

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Semaglutide treatment resulted in significant reductions in body mass index (BMI), waist circumference, and HbA1c
    2 context sentences
    Summary · context
    The objective of this 52-week, single-center, randomized trial was to compare the effects of subcutaneous semaglutide administered once weekly and oral sitagliptin administered once daily on anthropometric measurements and lipoprotein subfractions measured by Lipoprint gelelectrophoresis in patients with type 2 diabetes mellitus (T2DM).
    Summary · context
    A total of 34 obese individuals with T2DM were enrolled in the study and randomly assigned to receive semaglutide (n = 18) or sitagliptin (n = 16).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In obese adults with type 2 diabetes, 52 weeks of subcutaneous semaglutide significantly reduced HbA1c.

    In plain wordsIn obese adults with type 2 diabetes, a year of semaglutide lowered HbA1c, a measure of long-term blood sugar.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c
    Study

    n = 18

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Semaglutide treatment resulted in significant reductions in body mass index (BMI), waist circumference, and HbA1c
    2 context sentences
    Summary · context
    The objective of this 52-week, single-center, randomized trial was to compare the effects of subcutaneous semaglutide administered once weekly and oral sitagliptin administered once daily on anthropometric measurements and lipoprotein subfractions measured by Lipoprint gelelectrophoresis in patients with type 2 diabetes mellitus (T2DM).
    Summary · context
    A total of 34 obese individuals with T2DM were enrolled in the study and randomly assigned to receive semaglutide (n = 18) or sitagliptin (n = 16).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In obese adults with type 2 diabetes, 52 weeks of subcutaneous semaglutide reduced LDL cholesterol.

    In plain wordsIn obese adults with type 2 diabetes, a year of semaglutide lowered LDL cholesterol.

    Peptide
    Semaglutide
    Outcome
    DecreaseLDL cholesterol
    Study

    n = 18

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    along with improvements in lipid parameters, including reductions in LDL cholesterol and non-HDL cholesterol levels
    2 context sentences
    Summary · context
    The objective of this 52-week, single-center, randomized trial was to compare the effects of subcutaneous semaglutide administered once weekly and oral sitagliptin administered once daily on anthropometric measurements and lipoprotein subfractions measured by Lipoprint gelelectrophoresis in patients with type 2 diabetes mellitus (T2DM).
    Summary · context
    A total of 34 obese individuals with T2DM were enrolled in the study and randomly assigned to receive semaglutide (n = 18) or sitagliptin (n = 16).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In obese adults with type 2 diabetes, 52 weeks of subcutaneous semaglutide reduced non-HDL cholesterol.

    In plain wordsIn obese adults with type 2 diabetes, a year of semaglutide lowered non-HDL cholesterol.

    Peptide
    Semaglutide
    Outcome
    DecreaseNon-HDL cholesterol
    Study

    n = 18

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    along with improvements in lipid parameters, including reductions in LDL cholesterol and non-HDL cholesterol levels
    2 context sentences
    Summary · context
    The objective of this 52-week, single-center, randomized trial was to compare the effects of subcutaneous semaglutide administered once weekly and oral sitagliptin administered once daily on anthropometric measurements and lipoprotein subfractions measured by Lipoprint gelelectrophoresis in patients with type 2 diabetes mellitus (T2DM).
    Summary · context
    A total of 34 obese individuals with T2DM were enrolled in the study and randomly assigned to receive semaglutide (n = 18) or sitagliptin (n = 16).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In obese adults with type 2 diabetes, 52 weeks of subcutaneous semaglutide shifted LDL subfractions toward a less atherogenic profile.

    In plain wordsIn obese adults with type 2 diabetes, a year of semaglutide shifted LDL particles toward a less harmful profile.

    Peptide
    Semaglutide
    Outcome
    MixedLDL subfraction distribution
    Study

    n = 18

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    redistribution of LDL and HDL subfractions toward a less atherogenic profile.
    2 context sentences
    Summary · context
    The objective of this 52-week, single-center, randomized trial was to compare the effects of subcutaneous semaglutide administered once weekly and oral sitagliptin administered once daily on anthropometric measurements and lipoprotein subfractions measured by Lipoprint gelelectrophoresis in patients with type 2 diabetes mellitus (T2DM).
    Summary · context
    A total of 34 obese individuals with T2DM were enrolled in the study and randomly assigned to receive semaglutide (n = 18) or sitagliptin (n = 16).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In obese adults with type 2 diabetes, 52 weeks of subcutaneous semaglutide shifted HDL subfractions toward a less atherogenic profile.

    In plain wordsIn obese adults with type 2 diabetes, a year of semaglutide shifted HDL particles toward a less harmful profile.

    Peptide
    Semaglutide
    Outcome
    MixedHDL subfraction distribution
    Study

    n = 18

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    redistribution of LDL and HDL subfractions toward a less atherogenic profile.
    2 context sentences
    Summary · context
    The objective of this 52-week, single-center, randomized trial was to compare the effects of subcutaneous semaglutide administered once weekly and oral sitagliptin administered once daily on anthropometric measurements and lipoprotein subfractions measured by Lipoprint gelelectrophoresis in patients with type 2 diabetes mellitus (T2DM).
    Summary · context
    A total of 34 obese individuals with T2DM were enrolled in the study and randomly assigned to receive semaglutide (n = 18) or sitagliptin (n = 16).
  8. 08HumanRandomized controlled trialMechanism

    In obese adults with type 2 diabetes, changes in lipoprotein subfractions were not explained by changes in BMI or HbA1c.

    In plain wordsIn obese adults with type 2 diabetes, changes in cholesterol particle types were not explained by changes in weight or HbA1c.

    Peptide
    Semaglutide
    Outcome
    No significant changeDependence of lipoprotein subfraction changes on BMI and HbA1c change
    Study

    n: not reported in source

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Multivariate regression analysis demonstrated that fluctuations in lipoprotein subfractions were not influenced by changes in BMI or HbA1c.
    2 context sentences
    Summary · context
    The objective of this 52-week, single-center, randomized trial was to compare the effects of subcutaneous semaglutide administered once weekly and oral sitagliptin administered once daily on anthropometric measurements and lipoprotein subfractions measured by Lipoprint gelelectrophoresis in patients with type 2 diabetes mellitus (T2DM).
    Summary · context
    A total of 34 obese individuals with T2DM were enrolled in the study and randomly assigned to receive semaglutide (n = 18) or sitagliptin (n = 16).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.